The scaffolding protein Flot2 promotes cytoneme-based transport of Wnt3 in gastric cancer

  1. Daniel Routledge
  2. Sally Rogers
  3. Yosuke Ono
  4. Lucy Brunt
  5. Valerie Meniel
  6. Giusy Tornillo
  7. Hassan Ashktorab
  8. Toby Phesse
  9. Steffen Scholpp  Is a corresponding author
  1. University of Exeter, United Kingdom
  2. Cardiff University, United Kingdom
  3. Howard University, United States

Abstract

The Wnt/β-catenin signalling pathway regulates multiple cellular processes during development and many diseases, including cell proliferation, migration, and differentiation. Despite their hydrophobic nature, Wnt proteins exert their function over long distances to induce paracrine signalling. Recent studies have identified several factors involved in Wnt secretion, however, our understanding of how Wnt ligands are transported between cells to interact with their cognate receptors is still debated. Here, we demonstrate that gastric cancer cells utilise cytonemes to transport Wnt3 intercellularly to promote proliferation and cell survival. Furthermore, we identify the membrane-bound scaffolding protein Flotillin-2 (Flot2), frequently overexpressed in gastric cancer, as a modulator of these cytonemes. Together with the Wnt co-receptor and cytoneme initiator Ror2, Flot2 determines the number and length of Wnt3 cytonemes in gastric cancer. Finally, we show that Flotillins are also necessary for Wnt8a cytonemes during zebrafish embryogenesis, suggesting a conserved mechanism for Flotillin-mediated Wnt transport on cytonemes in development and disease.

Data availability

All data generated or analysed during this study are included in the manuscript, supporting files and source files; Supporting Data files and Source Data have been provided to all figures.

Article and author information

Author details

  1. Daniel Routledge

    Living Systems Institute, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  2. Sally Rogers

    Living Systems Institute, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  3. Yosuke Ono

    Living Systems Institute, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  4. Lucy Brunt

    Living Systems Institute, University of Exeter, Exeter, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  5. Valerie Meniel

    The European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  6. Giusy Tornillo

    The European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
  7. Hassan Ashktorab

    Department of Medicine, Howard University, Washington, United States
    Competing interests
    The authors declare that no competing interests exist.
  8. Toby Phesse

    The European Cancer Stem Cell Research Institute, Cardiff University, Cardiff, United Kingdom
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0001-9568-4916
  9. Steffen Scholpp

    Living Systems Institute, University of Exeter, Exeter, United Kingdom
    For correspondence
    s.scholpp@exeter.ac.uk
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-4903-9657

Funding

Medical Research Council (MR/N0137941/1)

  • Daniel Routledge

Medical Research Council (MR/S007970/1)

  • Sally Rogers
  • Steffen Scholpp

Biotechnology and Biological Sciences Research Council (BB/S016295/1)

  • Yosuke Ono
  • Lucy Brunt
  • Steffen Scholpp

Medical Research Council (MR/R026424/1)

  • Valerie Meniel
  • Giusy Tornillo
  • Toby Phesse

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: Zebrafish care and all experimental procedures were carried out in accordance with the European Communities Council Directive (2010/63/EU) and Animals Scientific Procedures Act (ASPA) 1986. Zebrafish experimental procedures were carried out under personal and project licenses granted by the UK Home Office under ASPA, and ethically approved by the Animal Welfare and Ethical Review Body at the University of Exeter.

Reviewing Editor

  1. Julia Christina Gross, Health and Medical University

Version history

  1. Preprint posted: January 8, 2022 (view preprint)
  2. Received: January 26, 2022
  3. Accepted: August 27, 2022
  4. Accepted Manuscript published: August 30, 2022 (version 1)
  5. Version of Record published: September 8, 2022 (version 2)

Copyright

© 2022, Routledge et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 1,103
    Page views
  • 257
    Downloads
  • 1
    Citations

Article citation count generated by polling the highest count across the following sources: Crossref, PubMed Central, Scopus.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Daniel Routledge
  2. Sally Rogers
  3. Yosuke Ono
  4. Lucy Brunt
  5. Valerie Meniel
  6. Giusy Tornillo
  7. Hassan Ashktorab
  8. Toby Phesse
  9. Steffen Scholpp
(2022)
The scaffolding protein Flot2 promotes cytoneme-based transport of Wnt3 in gastric cancer
eLife 11:e77376.
https://doi.org/10.7554/eLife.77376

Further reading

    1. Cancer Biology
    Elena Farmaki, Aritro Nath ... Andrea H Bild
    Research Article

    The mTOR inhibitor, everolimus, is an important clinical management component of metastatic ER+ breast cancer (BC). However, most patients develop resistance and progress on therapy, highlighting the need to discover strategies that increase mTOR inhibitor effectiveness. We developed ER+ BC cell lines, sensitive or resistant to everolimus, and discovered that combination treatment of ONC201/TIC10 with everolimus inhibited cell growth in 2D/3D in vitro studies. We confirmed increased therapeutic response in primary patient cells progressing on everolimus, supporting clinical relevance. We show that ONC201/TIC10 mechanism in metastatic ER+ BC cells involves oxidative phosphorylation inhibition and stress response activation. Transcriptomic analysis in everolimus resistant breast patient tumors and mitochondrial functional assays in resistant cell lines demonstrated increased mitochondrial respiration dependency, contributing to ONC201/TIC10 sensitivity. We propose that ONC201/TIC10 and modulation of mitochondrial function may provide an effective add-on therapy strategy for patients with metastatic ER+ BCs resistant to mTOR inhibitors.

    1. Cancer Biology
    2. Computational and Systems Biology
    Megan E Kelley, Adi Y Berman ... Gregory P Way
    Research Article

    Drug resistance is a challenge in anticancer therapy. In many cases, cancers can be resistant to the drug prior to exposure, i.e., possess intrinsic drug resistance. However, we lack target-independent methods to anticipate resistance in cancer cell lines or characterize intrinsic drug resistance without a priori knowledge of its cause. We hypothesized that cell morphology could provide an unbiased readout of drug resistance. To test this hypothesis, we used HCT116 cells, a mismatch repair-deficient cancer cell line, to isolate clones that were resistant or sensitive to bortezomib, a well-characterized proteasome inhibitor and anticancer drug to which many cancer cells possess intrinsic resistance. We then expanded these clones and measured high-dimensional single-cell morphology profiles using Cell Painting, a high-content microscopy assay. Our imaging- and computation-based profiling pipeline identified morphological features that differed between resistant and sensitive cells. We used these features to generate a morphological signature of bortezomib resistance. We then employed this morphological signature to analyze a set of HCT116 clones (five resistant and five sensitive) that had not been included in the signature training dataset, and correctly predicted sensitivity to bortezomib in seven cases, in the absence of drug treatment. This signature predicted bortezomib resistance better than resistance to other drugs targeting the ubiquitin-proteasome system. Our results establish a proof-of-concept framework for the unbiased analysis of drug resistance using high-content microscopy of cancer cells, in the absence of drug treatment.